Symbols / BBIO Stock $65.95 +1.96% BridgeBio Pharma, Inc.

Healthcare • Biotechnology • United States • NMS
BBIO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Neil Kumar Ph.D.
Exch · Country NMS · United States
Market Cap 12.92B
Enterprise Value 14.48B
Income -721.55M
Sales 579.96M
FCF (ttm) -317.91M
Book/sh -10.71
Cash/sh 4.80
Employees 834
Insider 10d —
IPO Jun 27, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 168.38
PEG —
P/S 22.27
P/B -6.16
P/C —
EV/EBITDA -29.02
EV/Sales 24.96
Quick Ratio 1.40
Current Ratio 1.52
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -3.74
EPS next Y 0.39
EPS Growth —
Revenue Growth 66.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-04
Earnings (prior) 2026-05-07
ROA -27.98%
ROE —
ROIC —
Gross Margin 95.13%
Oper. Margin -54.47%
Profit Margin -124.42%
Shs Outstand 195.86M
Shs Float 162.87M
Insider Own 3.92%
Instit Own 100.23%
Short Float 13.69%
Short Ratio 9.84
Short Interest 24.03M
52W High 84.94
vs 52W High -22.36%
52W Low 31.77
vs 52W Low 107.59%
Beta 1.02
Impl. Vol. 3.13%
Rel Volume 0.90
Avg Volume 2.53M
Volume 2.28M
Target (mean) $101.87
Tgt Median $100.00
Tgt Low $80.00
Tgt High $157.00
# Analysts 23
Recom Strong_buy
Prev Close $64.68
Price $65.95
Change 1.96%
About

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$101.87
Mean price target
2. Current target
$65.95
Latest analyst target
3. DCF / Fair value
$-29.22
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$65.95
Low
$80.00
High
$157.00
Mean
$101.87

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-11 main HC Wainwright & Co. Buy → Buy $110
2026-05-08 main Evercore ISI Group Outperform → Outperform $130
2026-04-29 main Truist Securities Buy → Buy $102
2026-04-29 reit HC Wainwright & Co. Buy → Buy $100
2026-04-28 reit Mizuho Outperform → Outperform $106
2026-04-27 reit HC Wainwright & Co. Buy → Buy $100
2026-04-09 init RBC Capital — → Outperform $100
2026-03-18 main Mizuho Outperform → Outperform $106
2026-03-10 main JP Morgan Overweight → Overweight $94
2026-03-10 init William Blair — → Outperform —
2026-02-25 main Truist Securities Buy → Buy $95
2026-02-25 main Oppenheimer Outperform → Outperform $81
2026-02-25 main Morgan Stanley Overweight → Overweight $98
2026-02-25 main Evercore ISI Group Outperform → Outperform $125
2026-02-17 main HC Wainwright & Co. Buy → Buy $100
2026-02-13 main Oppenheimer Outperform → Outperform $83
2026-02-13 main Wells Fargo Overweight → Overweight $98
2026-01-28 init Barclays — → Overweight $80
2026-01-20 main Wells Fargo Overweight → Overweight $88
2026-01-08 main Truist Securities Buy → Buy $86
News
RSS: Latest BBIO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-30 APULI MARICEL Officer — 2,000 $71.58 $143,160
2026-04-10 KUMAR NEIL Chief Executive Officer — 80,000 $73.64 $5,968,780
2026-03-18 TRIMARCHI THOMAS President — 59,041 $0.00 $0
2026-03-18 APULI MARICEL Officer — 14,170 $0.00 $0
2026-03-13 KUMAR NEIL Chief Executive Officer — 80,000 $68.36 $5,501,068
2026-03-10 VALANTINE HANNAH A. Director — 8,671 $27.36 $237,239
2026-03-10 VALANTINE HANNAH A. Director — 8,671 $72.00 $624,312
2026-03-04 ELLIS ANDREA Director — 64,921 $8.45 $548,582
2026-03-04 ELLIS ANDREA Director — 64,921 $64.87 $4,211,302
2026-02-27 VALANTINE HANNAH A. Director — 25,484 $48.45 $1,234,700
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
502.08
+126.26%
221.90
+2285.27%
9.30
-88.02%
77.65
Operating Revenue
502.08
+126.26%
221.90
+2285.27%
9.30
-88.02%
77.65
Cost Of Revenue
20.96
+440.54%
3.88
+58.54%
2.45
-28.77%
3.43
Reconciled Cost Of Revenue
20.96
+440.54%
3.88
+58.54%
2.45
-28.77%
3.43
Gross Profit
481.11
+120.67%
218.02
+3079.58%
6.86
-90.76%
74.21
Operating Expense
983.18
+23.61%
795.39
+31.19%
606.30
+11.73%
542.65
Research And Development
451.95
-10.76%
506.46
+11.14%
455.71
+14.08%
399.46
Selling General And Administration
531.23
+83.86%
288.93
+91.87%
150.59
+5.17%
143.19
Total Expenses
1,004.14
+25.63%
799.27
+31.30%
608.75
+11.47%
546.09
Operating Income
-502.06
+13.04%
-577.37
+3.68%
-599.44
-27.97%
-468.44
Total Operating Income As Reported
-523.41
+11.73%
-592.97
+2.37%
-607.37
-18.58%
-512.20
EBITDA
-548.83
-25.64%
-436.83
+22.75%
-565.47
-42.28%
-397.44
Normalized EBITDA
-506.33
+11.63%
-572.96
-2.76%
-557.54
-61.39%
-345.46
Reconciled Depreciation
5.43
-10.55%
6.08
-6.45%
6.49
-4.09%
6.77
EBIT
-554.26
-25.14%
-442.90
+22.56%
-571.96
-41.50%
-404.21
Total Unusual Items
-42.50
-131.22%
136.13
+1817.46%
-7.93
+84.75%
-51.99
Total Unusual Items Excluding Goodwill
-42.50
-131.22%
136.13
+1817.46%
-7.93
+84.75%
-51.99
Special Income Charges
-42.50
-131.22%
136.13
+1817.46%
-7.93
+81.89%
-43.77
Other Special Charges
21.16
-20.44%
26.59
—
—
Impairment Of Capital Assets
0.00
-100.00%
0.27
0.00
-100.00%
12.72
Restructuring And Mergern Acquisition
21.35
+39.21%
15.33
+93.46%
7.93
-74.47%
31.05
Write Off
—
—
7.21
-65.23%
20.74
Net Income
-724.93
-35.31%
-535.76
+16.70%
-643.20
-33.67%
-481.18
Pretax Income
-732.50
-35.10%
-542.19
+17.00%
-653.25
-34.79%
-484.65
Net Non Operating Interest Income Expense
-158.39
-93.06%
-82.04
-29.71%
-63.25
+13.23%
-72.90
Interest Expense Non Operating
178.24
+79.52%
99.29
+22.14%
81.29
+1.06%
80.44
Net Interest Income
-158.39
-93.06%
-82.04
-29.71%
-63.25
+13.23%
-72.90
Interest Expense
178.24
+79.52%
99.29
+22.14%
81.29
+1.06%
80.44
Interest Income Non Operating
19.85
+15.10%
17.25
-4.37%
18.04
+139.17%
7.54
Interest Income
19.85
+15.10%
17.25
-4.37%
18.04
+139.17%
7.54
Other Income Expense
-72.05
-161.47%
117.22
+1141.16%
9.44
-83.34%
56.68
Other Non Operating Income Expenses
43.06
+250.86%
12.27
-29.35%
17.37
-84.02%
108.67
Gain On Sale Of Security
—
8.14
-55.54%
18.30
+322.57%
-8.22
Gain On Sale Of Business
0.00
-100.00%
178.32
0.00
0.00
Tax Provision
0.43
-62.27%
1.15
0.00
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
-8.93
-131.22%
28.59
0.00
0.00
Net Income Including Noncontrolling Interests
-732.94
-34.89%
-543.35
+16.82%
-653.25
-34.79%
-484.65
Net Income From Continuing Operation Net Minority Interest
-724.93
-35.31%
-535.76
+16.70%
-643.20
-33.67%
-481.18
Net Income From Continuing And Discontinued Operation
-724.93
-35.31%
-535.76
+16.70%
-643.20
-33.67%
-481.18
Net Income Continuous Operations
-732.94
-34.89%
-543.35
+16.82%
-653.25
-34.79%
-484.65
Minority Interests
8.01
+5.56%
7.58
-24.52%
10.05
+189.68%
3.47
Normalized Income
-691.35
-7.47%
-643.30
-1.26%
-635.28
-48.02%
-429.20
Net Income Common Stockholders
-724.93
-35.31%
-535.76
+16.70%
-643.20
-33.67%
-481.18
Diluted EPS
-3.78
-31.25%
-2.88
+27.09%
-3.95
-21.17%
-3.26
Basic EPS
-3.78
-31.25%
-2.88
+27.09%
-3.95
-21.17%
-3.26
Basic Average Shares
191.53
+2.93%
186.08
+14.30%
162.79
+10.39%
147.47
Diluted Average Shares
191.53
+2.93%
186.08
+14.30%
162.79
+10.39%
147.47
Diluted NI Availto Com Stockholders
-724.93
-35.31%
-535.76
+16.70%
-643.20
-33.67%
-481.18
Earnings From Equity Interest
-72.61
-132.84%
-31.18
0.00
0.00
Gain On Sale Of PPE
—
—
—
-7.50
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
936.02
+1.82%
919.34
+68.26%
546.38
-12.30%
623.04
Current Assets
797.75
+10.69%
720.69
+50.90%
477.59
-12.98%
548.85
Cash Cash Equivalents And Short Term Investments
587.48
-13.75%
681.10
+56.62%
434.88
-7.85%
471.92
Cash And Cash Equivalents
570.12
-16.29%
681.10
+81.18%
375.94
-0.20%
376.69
Other Short Term Investments
17.36
0.00
-100.00%
58.95
-38.10%
95.23
Receivables
139.44
+2853.07%
4.72
+169.67%
1.75
-89.75%
17.08
Accounts Receivable
139.44
+2853.07%
4.72
+169.67%
1.75
—
Other Receivables
—
—
1.75
-89.75%
17.08
Inventory
26.75
0.00
—
—
Prepaid Assets
—
—
—
21.92
Restricted Cash
—
0.13
-99.24%
16.65
-56.10%
37.93
Other Current Assets
44.07
+26.39%
34.87
+43.46%
24.30
+10.87%
21.92
Total Non Current Assets
138.28
-30.39%
198.65
+188.78%
68.79
-7.27%
74.18
Net PPE
13.52
+5.77%
12.78
-35.60%
19.84
-21.40%
25.25
Gross PPE
13.52
+5.77%
12.78
-35.60%
19.84
-21.40%
25.25
Other Properties
13.52
+5.77%
12.78
-35.60%
19.84
-21.40%
25.25
Goodwill And Other Intangible Assets
28.08
+17.35%
23.93
-9.09%
26.32
-8.33%
28.71
Other Intangible Assets
—
—
—
28.71
Investments And Advances
79.97
-44.37%
143.75
0.00
—
Long Term Equity Investment
79.97
-44.37%
143.75
0.00
—
Other Non Current Assets
16.71
-8.15%
18.20
-19.58%
22.62
+11.87%
20.22
Total Liabilities Net Minority Interest
3,012.61
+26.74%
2,376.95
+25.84%
1,888.91
+1.12%
1,867.96
Current Liabilities
287.97
+86.51%
154.40
+7.34%
143.84
+18.46%
121.43
Payables And Accrued Expenses
186.66
+143.00%
76.82
+0.74%
76.25
-2.67%
78.34
Payables
36.23
+276.67%
9.62
-9.73%
10.65
-7.81%
11.56
Accounts Payable
36.23
+276.67%
9.62
-9.73%
10.65
-7.81%
11.56
Current Accrued Expenses
150.44
+123.87%
67.20
+2.45%
65.59
-1.78%
66.78
Pensionand Other Post Retirement Benefit Plans Current
76.70
+31.50%
58.33
+1.67%
57.37
+83.55%
31.26
Current Debt And Capital Lease Obligation
6.19
+37.42%
4.51
+9.16%
4.13
+12.33%
3.67
Current Capital Lease Obligation
6.19
+37.42%
4.51
+9.16%
4.13
+12.33%
3.67
Current Deferred Liabilities
18.41
+24.84%
14.75
+141.93%
6.10
-25.26%
8.16
Current Deferred Revenue
7.19
-50.77%
14.60
+139.57%
6.10
-25.26%
8.16
Total Non Current Liabilities Net Minority Interest
2,724.64
+22.59%
2,222.55
+27.36%
1,745.07
-0.08%
1,746.53
Long Term Debt And Capital Lease Obligation
1,856.28
+7.54%
1,726.08
-0.55%
1,735.71
+0.92%
1,719.89
Long Term Debt
1,852.47
+7.62%
1,721.38
-0.31%
1,726.73
+1.12%
1,707.62
Long Term Capital Lease Obligation
3.81
-18.85%
4.70
-47.71%
8.98
-26.83%
12.27
Non Current Deferred Liabilities
868.11
+74.96%
496.19
+13213.28%
3.73
—
Non Current Deferred Revenue
13.08
-23.49%
17.09
+358.68%
3.73
—
Other Non Current Liabilities
0.24
-14.69%
0.29
-94.92%
5.63
-78.85%
26.64
Stockholders Equity
-2,086.61
-42.15%
-1,467.90
-8.39%
-1,354.26
-7.94%
-1,254.62
Common Stock Equity
-2,086.61
-42.15%
-1,467.90
-8.39%
-1,354.26
-7.94%
-1,254.62
Capital Stock
0.20
+3.06%
0.20
+8.29%
0.18
+15.29%
0.16
Common Stock
0.20
+3.06%
0.20
+8.29%
0.18
+15.29%
0.16
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
202.37
+3.13%
196.24
+8.25%
181.27
+15.60%
156.82
Ordinary Shares Number
194.77
+2.49%
190.04
+8.55%
175.08
+16.24%
150.63
Treasury Shares Number
7.60
+22.70%
6.19
+0.00%
6.19
+0.00%
6.19
Additional Paid In Capital
2,057.65
+8.12%
1,903.15
+28.50%
1,481.03
+57.77%
938.70
Retained Earnings
-3,821.19
-23.41%
-3,096.26
-20.92%
-2,560.50
-33.49%
-1,918.15
Gains Losses Not Affecting Retained Earnings
0.01
+50.00%
0.01
-74.19%
0.03
+109.45%
-0.33
Treasury Stock
323.28
+17.55%
275.00
+0.00%
275.00
+0.00%
275.00
Minority Interest
10.03
-2.56%
10.29
-12.20%
11.72
+20.93%
9.69
Other Equity Adjustments
0.01
+50.00%
0.01
-74.19%
0.03
+109.45%
-0.33
Total Equity Gross Minority Interest
-2,076.58
-42.46%
-1,457.61
-8.57%
-1,342.54
-7.84%
-1,244.92
Total Capitalization
-234.14
-192.37%
253.48
-31.95%
372.47
-17.78%
453.00
Working Capital
509.78
-9.98%
566.29
+69.68%
333.75
-21.92%
427.43
Invested Capital
-234.14
-192.37%
253.48
-31.95%
372.47
-17.78%
453.00
Total Debt
1,862.47
+7.62%
1,730.58
-0.53%
1,739.84
+0.94%
1,723.56
Net Debt
1,282.35
+23.27%
1,040.28
-22.99%
1,350.79
+1.49%
1,330.93
Capital Lease Obligations
10.00
+8.70%
9.20
-29.80%
13.11
-17.81%
15.95
Net Tangible Assets
-2,114.69
-41.75%
-1,491.83
-8.06%
-1,380.58
-7.58%
-1,283.33
Tangible Book Value
-2,114.69
-41.75%
-1,491.83
-8.06%
-1,380.58
-7.58%
-1,283.33
Interest Payable
14.41
+30.35%
11.06
-37.75%
17.76
+1.49%
17.50
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-445.91
+14.37%
-520.73
+1.33%
-527.72
-25.80%
-419.49
Cash Flow From Continuing Operating Activities
-445.91
+14.37%
-520.73
+1.33%
-527.72
-25.80%
-419.49
Net Income From Continuing Operations
-732.94
-34.89%
-543.35
+16.82%
-653.25
-34.79%
-484.65
Depreciation Amortization Depletion
5.43
-10.55%
6.08
-6.45%
6.49
-4.09%
6.77
Depreciation And Amortization
5.43
-10.55%
6.08
-6.45%
6.49
-4.09%
6.77
Other Non Cash Items
136.01
+584.38%
19.87
-14.14%
23.15
+126.17%
-88.45
Stock Based Compensation
133.02
+38.86%
95.80
-11.88%
108.71
+18.73%
91.56
Asset Impairment Charge
—
0.27
0.00
-100.00%
12.72
Operating Gains Losses
84.93
+166.00%
-128.68
-653.73%
-17.07
-217.88%
14.48
Gain Loss On Investment Securities
-8.83
-8.57%
-8.14
+55.57%
-18.31
-322.74%
8.22
Unrealized Gain Loss On Investment Securities
-21.30
-757.26%
-2.48
-209.46%
-0.80
—
Change In Working Capital
-51.06
-259.37%
32.04
+533.62%
5.06
-81.99%
28.08
Change In Receivables
-134.72
-4434.57%
-2.97
-119.38%
15.33
+1.05%
15.17
Changes In Account Receivables
-134.72
-4434.57%
-2.97
-119.38%
15.33
+1.05%
15.17
Change In Inventory
-25.31
0.00
0.00
—
Change In Prepaid Assets
-8.78
+36.94%
-13.92
-415.10%
-2.70
-135.22%
7.67
Change In Payables And Accrued Expense
56.79
+108.59%
27.23
+3645.12%
0.73
+104.93%
-14.75
Change In Accrued Expense
30.18
+17.38%
25.71
+1352.56%
-2.05
+85.74%
-14.40
Change In Payable
26.61
+1659.85%
1.51
-45.61%
2.78
+896.56%
-0.35
Change In Account Payable
26.61
+1659.85%
1.51
-45.61%
2.78
+896.56%
-0.35
Change In Other Working Capital
66.38
+154.69%
26.06
+1456.79%
-1.92
-112.59%
15.26
Change In Other Current Assets
1.11
-27.82%
1.54
+199.74%
-1.55
-114.09%
10.97
Change In Other Current Liabilities
-6.55
-10.93%
-5.90
-22.22%
-4.83
+22.67%
-6.25
Investing Cash Flow
-24.49
-140.29%
60.78
+12.49%
54.03
-88.08%
453.15
Cash Flow From Continuing Investing Activities
-24.49
-140.29%
60.78
+12.49%
54.03
-88.08%
453.15
Net PPE Purchase And Sale
-1.10
-17.58%
-0.93
+28.56%
-1.31
+72.91%
-4.82
Purchase Of PPE
-1.10
-17.58%
-0.93
+28.56%
-1.31
+72.91%
-4.82
Capital Expenditure
-9.59
-7.68%
-8.91
-582.08%
-1.31
+79.34%
-6.32
Net Investment Purchase And Sale
-17.20
-138.95%
44.15
-20.94%
55.84
-83.55%
339.47
Purchase Of Investment
-28.20
+75.28%
-114.08
+16.89%
-137.26
+28.90%
-193.06
Sale Of Investment
11.00
-93.05%
158.23
-18.06%
193.11
-63.74%
532.52
Net Business Purchase And Sale
0.00
+100.00%
-0.14
+72.17%
-0.50
0.00
Purchase Of Business
0.00
+100.00%
-0.14
+72.17%
-0.50
0.00
Gain Loss On Sale Of Business
0.00
+100.00%
-178.32
-14469.14%
1.24
0.00
Net Intangibles Purchase And Sale
-8.49
-6.52%
-7.97
0.00
+100.00%
-1.50
Purchase Of Intangibles
-8.49
-6.52%
-7.97
0.00
+100.00%
-1.50
Net Other Investing Changes
—
—
-0.50
-100.42%
120.00
Financing Cash Flow
359.29
-52.00%
748.46
+65.76%
451.54
+3537.91%
-13.13
Cash Flow From Continuing Financing Activities
359.29
-52.00%
748.46
+65.76%
451.54
+3537.91%
-13.13
Net Issuance Payments Of Debt
116.00
+595.37%
-23.42
0.00
+100.00%
-20.49
Issuance Of Debt
575.00
+27.78%
450.00
0.00
0.00
Repayment Of Debt
-459.00
+3.05%
-473.42
0.00
+100.00%
-20.49
Long Term Debt Issuance
575.00
+27.78%
450.00
0.00
0.00
Long Term Debt Payments
-459.00
+3.05%
-473.42
0.00
+100.00%
-20.49
Net Long Term Debt Issuance
116.00
+595.37%
-23.42
0.00
+100.00%
-20.49
Net Common Stock Issuance
-62.50
-120.34%
307.21
-30.64%
442.93
+13358.83%
3.29
Common Stock Payments
-62.50
-730.48%
-7.53
-9.39%
-6.88
-340.74%
-1.56
Repurchase Of Capital Stock
-62.50
-730.48%
-7.53
-9.39%
-6.88
-340.74%
-1.56
Proceeds From Stock Option Exercised
34.15
+318.60%
8.16
-13.27%
9.41
+191.75%
3.22
Net Other Financing Charges
271.65
-40.49%
456.50
+57091.39%
-0.80
-195.70%
0.84
Changes In Cash
-111.10
-138.51%
288.51
+1402.42%
-22.15
-207.96%
20.52
Beginning Cash Position
683.24
+73.09%
394.73
-5.31%
416.88
+5.18%
396.37
End Cash Position
572.14
-16.26%
683.24
+73.09%
394.73
-5.31%
416.88
Free Cash Flow
-455.50
+14.00%
-529.63
-0.11%
-529.03
-24.24%
-425.81
Interest Paid Supplemental Data
43.76
-52.09%
91.34
+49.48%
61.11
+12.24%
54.44
Income Tax Paid Supplemental Data
1.20
—
—
—
Common Stock Issuance
0.00
-100.00%
314.74
-30.03%
449.81
+9170.61%
4.85
Dividends Received CFI
2.30
-91.04%
25.68
0.00
0.00
Earnings Losses From Equity Investments
72.61
+132.84%
31.18
0.00
0.00
Issuance Of Capital Stock
0.00
-100.00%
314.74
-30.03%
449.81
+9170.61%
4.85
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category